Boehringer Ingelheim wanted an in-depth understanding of the interaction mechanism of Afatinib (inhibitor of EGFR, HER2, and ErbB4).
An irreversible and complex interaction mechanism.
With an experimental design for an induced-fit mechanism, Beactica untangled the interaction mechanism using its SPR-based drug discovery platform.
The results from the SPR interaction analysis were used to formulate a mechanistic rationale for the distinct pharmacological features of Afatinib. The results explain the clinical activity seen in some patients resistant to antibody or kinase inhibitor therapy. The results from the collaboration were published in the Journal of Pharmacology and Experimental Therapeutics (JPET) in 2012.
Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharm Exp Therap, 343(2):342–50.
Sign up for the Beactica newsletter to receive our latest news and updates